The
present investigation reports a new fluorophore-tagged biodegradable
polycaprolactone (PCL) block copolymer FRET-probe for intracellular
imaging in cancer therapy. A hydroxyl functionalized π-conjugated
oligo-phenylenevinylene (OPV) chromophore was tailor-made, and it
was incorporated in a t-butyl ester substituted polycaprolactone
block copolymer via ring opening polymerization. This blue-luminescent
OPV-PCL triblock self-assembled as <200 nm spherical nanoparticles
(FRET donor), and it encapsulated water insoluble Nile red (NR, FRET
acceptor) to yield an OPV-NR FRET probe. Selective photo excitation
of the OPV chromophore in block nanoassemblies enabled the excitation
energy transfer from the OPV to NR and facilitated the efficient FRET
process in aqueous medium. Time-correlated fluorescent decay dynamics
and detailed photophysical studies were carried out to estimate the
Förster distance, donor–acceptor distance, and the excitation
energy transfer efficiency. These parameters confirmed the occurrence
of the FRET process within the confined nanoparticle environment.
The PCL chains in the FRET probe were susceptible to enzymatic biodegradation
in intracellular environments, and the degradation process controlled
the FRET on/off mechanism. Cytotoxicity studies revealed that the
FRET probe was biocompatible and nontoxic to cells, and the FRET-probe
was found to be readily taken up by the cancer cells, and it was internalized
in the cytoplasm and peri-nuclear environment. Selective photoexcitation
of the OPV chromophore in a confocal microscope exhibited dual emission
from the FRET probe. The cancer cells exhibited blue luminescence
(self-emission) with respect to the OPV chromophore (in the blue channel)
and bright red-luminescence from the NR dye followed by the FRET process
at the cellular level (in the red channel). The dual luminescence
characteristics, biodegradation and biocompatibility, make the newly
designed PCL-OPV-NR FRET probe an excellent biomedical nanodevice
for bioimaging applications, and the proof-of-concept was established
in cervical (HeLa) and breast cancer (MCF 7) cell lines.